About Graham Dempsey
Graham Dempsey, Ph.D., is founder and chief executive officer of Quiver Bioscience in Cambridge, Massachusetts. Quiver builds a drug discovery platform that pairs human neuron models and optical electrophysiology with AI. It also advances its own pipeline of therapeutics for neurological and pain disorders, including antisense programs. Quiver announced his appointment as chief executive officer on June 16, 2025.
Company releases call him a co-founder. In May 2025 he spoke for Quiver on a research collaboration with QurAlis on Fragile X syndrome. In February 2026 he did so for a collaboration and licensing agreement with Angelini Pharma on genetic epilepsies. In April 2026 he commented on an investment from the Porta family in Quiver's Dup15q syndrome program.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Graham Dempsey in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Graham Dempsey works with at each company, as listed on that company's latest Form D.
